Fairvalue-Calculator Fairvalue-Calculator
EN DE

SQZ Biotechnologies Company (SQZB) Fair Value & Analysis

Healthcare · US · Market cap $708K

Price$0.0240
Fair Value$0.0229
Upside-4.5%
Quality89/100
Evidence: Low Range $0.0213 – $0.0240

Fair value as of: Jun 26, 2026

✦ Find undervalued quality stocks — 34,000+ analysed Find stocks →

Analysis

SQZ Biotechnologies Company (SQZB) currently trades at $0.0240, while our model-based Fair Value estimate is $0.0229 — implying the stock looks roughly 4.5% overvalued today. We read business quality at 89/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

SQZ Biotechnologies Company, a clinical-stage biotechnology company, develops cell therapies for patients with cancer, infectious diseases, and other serious conditions in Massachusetts. Its lead product candidate is SQZ-PBMC-HPV, from its SQZ Antigen Presenting Cells platform, which is in a Phase I clinical trial as a monotherapy and in combination with immuno-oncology agents for the treatment of HPV16+ advanced or metastatic solid tumors, including cervical, head-and-neck, anal, penile, vulvar, and vaginal cancer. The company also develops SQZ-AAC-HPV and SQZ-eAPC-HPV, which is in a Phase I clinical trial for the treatment of HPV16+ advanced or metastatic solid tumors in monotherapy and in combinations with immune-oncology agents. Its additional platforms in development are SQZ Activating Antigen Carriers; and SQZ Tolerizing Antigen Carriers. The Company was incorporated in 2013 and is headquartered in Watertown, Massachusetts.

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -32% Regeneron Pharmaceuticals, Inc (REGN) -4% UCB SA (UCB) -23% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) +1% Alnylam Pharmaceuticals, Inc (ALNY) -82%

Frequently asked questions

Is SQZ Biotechnologies Company (SQZB) undervalued?
As of Jun 26, 2026, our model estimates a fair value of $0.0229 versus a price of $0.0240 — about −5% (overvalued). Model-based estimate, not financial advice.
What is the fair value of SQZB?
Our 21-model fair value for SQZ Biotechnologies Company is $0.0229 (as of Jun 26, 2026), built from audited fundamentals. The current price is $0.0240.
What is the quality score of SQZB?
SQZ Biotechnologies Company has a Quality Score of 89/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.